Table 1 Baseline clinical and laboratory data of outpatients with MNG treated with RAI with (group 1) or without (group 2) rhTSH pre-treatment (0.1 mg, on two consecutive days).
Group 1 (n = 19) | Group 2 (n = 21) | Significance | |
|---|---|---|---|
Age (yr), mean ± SD | 71.8 ± 6.7 | 70.6 ± 6.8 | ns |
Females/Males | 18/1 | 16/5 | ns |
BMI (kg/m2) | 27.6 ± 1.1 | 26.4 ± 0.7 | ns |
Previous surgery (n) | 3 | 3 | ns |
Previous 131I therapy (n) | 2 | 2 | ns |
Use of MMI before RAI (n) | 5 | 14 | P = 0.01 |
US TV (ml), mean ± SEM | 71.9 ± 8.1 | 79.5 ± 8.1 | ns |
(median; range) | 65.0; 39 – 171 | 72; 38–194 | |
TSH (mIU/l), mean ± SEM | 0.69 ± 0.11 | 0.50 ± 0.24 | P = 0.003 |
f-T3 (pmol/l), mean ± SEM | 5.1 ± 0.3 | 5.7 ± 0.1 | P = 0.005 |
f-T4 (pmol/l), mean ± SEM | 16.2 ± 0.8 | 16.6 ± 1.0 | ns |
Tg (μg/l), mean ± SEM | 93.5 ± 21.8 | 81.5 ± 14.6 | ns |
Positive thyroid antibodies (n) | 4 | 2 | ns |
Urinary iodine (μg/l), mean ± SEM | 97.2 ± 9.8 | 79.6 ± 12.9 | ns |
24-h RAIU (%), mean ± SEM | 35.2 ± 3.2 | 43.4 ± 2.9 | ns |
131 I activity (MBq), mean± SEM | 542.1 ± 18.3 | 549 ± 13.8 | ns |
(median; range) | 600; 370 – 600 | 555; 370 – 600 |